Rifaximin, a peculiar rifamycin derivative: Established and potential clinical use outside the gastrointestinal tract

Chemotherapy

Volumn 51, Issue SUPPL. 1, 2005, Pages 122-130

  Pelosini, Iva ^a   Scarpignato, Carmelo ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Antibiotic therapy; Periodontal disease; Rifamycin; Rifaximin; Skin infections; Vaginosis, bacterial

Indexed keywords

ANTIBIOTIC AGENT; METRONIDAZOLE; RIFAXIMIN;

ANTIBIOTIC PROPHYLAXIS; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; BACTERIUM CULTURE; CELLULITIS; CLINICAL FEATURE; ERYSIPELAS; GARDNERELLA VAGINALIS; HUMAN; INFECTION RISK; NECROTIZING FASCIITIS; PERIODONTAL DISEASE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SIDE EFFECT; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; SYSTEMIC THERAPY; VAGINITIS;

ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; FEMALE; HUMANS; PERIODONTAL DISEASES; PREGNANCY; RIFAMYCINS; SKIN DISEASES, BACTERIAL; VAGINOSIS, BACTERIAL;

EID: 18644380722     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081999     Document Type: Review

References (71)

1. Gillis JC, Brogden RN: Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995;49:467-484.
2. Scarpignato C, Pelosini I: Rifaximin, a poorly absorbed antibiotic: Pharmacology and clinical potential. Chemotherapy 2005;51(suppl 1):36-66.
3. DuPont HL: Community-acquired diarrheal disease in western countries: Applications of nonabsorbable oral antibiotic therapy. Adv Stud Med 2003;3(suppl A):S945-S950.
4. Cunha BA: Antibiotic side effects. Med Clin North Am 2001;85:149-185.
5. Ericsson CD, DuPont HL: Rifaximin in the treatment of infectious diarrhea. Chemotherapy 2005;51(suppl 1):73-80.
6. Hart AL, Stagg AJ, Frame M, Graffner H, Glise H, Falk P, Kamm MA: The role of the gut flora in health and disease, and its modification as therapy. Aliment Pharmacol Ther 2002;16:1383-1393.
7. Guarner F, Malagelada JR: Gut flora in health and disease. Lancet 2003;361:512-519.
8. Venturini AP, Bertoli D, Marchi E: Transcutaneous absorption of a topical rifamycin preparation: Rifaximin (L/105). Drugs Exp Clin Res 1987;13:231-232.
9. Berlö JA, Debruyne HJ, Gortz JP: A prospective study in healthy volunteers of the topical absorption of a 5% rifaximin cream. Drugs Exp Clin Res 1994;20:205-208.
10. Hoover WW, Gerlach EH, Hoban DJ, Eliopoulos GM, Pfaller MA, Jones RN: Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis 1993;16:111-118.
11. Prasad ES, Wenman WM: In vitro activity of rifaximin, a topical rifamycin derivative, against Chlamydia trachomatis. Diagn Microbiol Infect Dis 1993;16:135-136.
12. Minabe M, Suzuki F, Umemoto T: Intra-pocket antibiotic therapy using resorbable and non-resorbable slow-release devices containing tetracycline. Periodontal Clin Investig 2000;22:14-21.
13. Roth RR, James WD: Microbiology of the skin: Resident flora, ecology, infection. J Am Acad Dermatol 1989;20:367-390.
14. Swartz MN, Weinberg AN: General considerations of bacterial diseases; in Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI (eds): Fitzpatrick's Dermatology in General Medicine (book on CD-ROM), ed 5. New York, McGraw-Hill, 1999.
15. Update on topical antibiotic therapy: Changing antibiotic susceptibility patterns and clinical implications. Proceedings from a clinical roundtable. November 9, 2002, Scottsdale, Arizona, USA. Cutis 2003;71(3 suppl):2-24.
16. Chiller K, Selkin BA, Murakawa GJ: Skin microflora and bacterial infections of the skin. J Investig Dermatol 2001;6:170-174.
17. Guay DR: Treatment of bacterial skin and skin structure infections. Expert Opin Pharmacother 2003;4:1259-1275.
18. Spann CT, Taylor SC, Weinberg JM: Topical antimicrobial agents in dermatology. Dis Mon 2004;50:407-421.
19. Espersen F: Resistance to antibiotics used in dermatological practice. Br J Dermatol 1998; 139(suppl 53):4-8.
20. Tempera G, Pinizzotto MR, Oliveri S: Microbiological-clinical study on the selection of resistant bacterial strains during topical treatment pyodermatitis with rifaximin cream. Stampa Med Eur (Rome) 1993;13:29-36.
21. Ena P, Zanetti S, Sechi L, Fadda G: Open study on rifaximin topical treatment for skin infections due to pyogenic bacteria. NAM (Milan) 1993;9:325-328.
22. Lazzaro C, Calaciura C, Spitalieri S, Lazzaro GC: Treatment of pyogenic skin infections: Results of a controlled trial with a new topical preparation (in Italian). Aggiornamenti Med Chir (Rome) 1989;13:1-11.
23. Marincola Cattaneo V, Attania A, Palazzini E, Monti A: Topic use of rifaximin in the treatment of pyodermitis (in Italian). Biol Med (Rome) 1988;10:69-78.
24. Lazzaro C, Salanitri T, Spitaleri S, Lazzaro Danzuso GC: Effectiveness and tolerance of topical rifaximin treatment for pyodermatosis. Clinical controlled trial vs chlortetracycline. Med Praxis (Milan) 1992;13:1-11.
25. Palazzini E, Palmerio B: Treatment of pyogenic skin infections with rifaximin cream. Eur Rev Med Pharmacol Sci 1993;15:87-92.
26. Moroni P, Da Valli R, Carboni G: Controlled clinical trial of topical rifaximin treatment for pyodermatitis. Aggiornamenti Med Chir (Rome) 1993;11:506-517.
27. Pasi F, Palazzini E: Assessment of efficacy and tolerance of rifaximin in the topical treatment of pyodermia: Controlled study vs. oxytetracycline. Derm Exper (Rome) 1993;8:13-20.
28. Cannata G, Piccardo G: Single-blind study of rifaximin effectiveness and safety for the topical treatment of bacterial skin infections. Biol Med (Rome)1993;15:7-19.
29. Rafanelli A, Rafanelli G, Palazzini E: Effectiveness and safety of a new topical antibiotic cream for use in patients with bacterial skin infection. Prog Rep (Rome) 1993;5:21-29.
30. Della Marchina M, Renzi G, Renzi C, Palazzini E: Rifaximin in the local treatment of pyodermia: A controlled clinical trial versus oxytetracycline. Biol Med (Rome) 1993;15:21-34.
31. Morris SD, Rycroft RJ, White IR, Wakelin SH, McFadden JP: Comparative frequency of patch test reactions to topical antibiotics. Br J Dermatol 2002;146:1047-1051.
32. Marks JG Jr, Belsito DV, DeLeo VA, Fowler JF Jr, Fransway AF, Maibach HI, Mathias CG, Pratt MD, Rietschel RL, Sherertz EF, Storrs FJ, Taylor JS: North American Contact Dermatitis Group patch test results for the detection of delayed-type hypersensitivity to topical allergens. J Am Acad Dermatol 1998;38:911-918.
33. Dire DJ, Coppola M, Dwyer DA, Lorette JJ, Karr JL: Prospective evaluation of topical antibiotics for preventing infections in uncomplicated soft-tissue wounds repaired in the ED. Acad Emerg Med 1995;2:4-10.
34. Majeroni BA: Bacterial vaginosis: An update. Am Fam Physician 1998;57:1285-1289.
35. Hillier SL, Holmes KK: Bacterial vaginosis; in Holmes KK, Mardh PA, Sparling PF, et al (eds): Sexually Transmitted Diseases. New York, McGraw-Hill, 1999, pp 563-587.
36. Hill GB: The microbiology of bacterial vaginosis. Am J Obstet Gynecol 1993;169:450-454.
37. Sobel JD: Bacterial vaginosis. Annu Rev Med 2000;51:349-356.
38. McDonald H, Brocklehurst P, Parsons J, Vigneswaran R: Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 2003;2:CD000262.
39. Joesoef M, Schmid G: Bacterial vaginosis. Clin Evid 2003;9:1712-1720.
40. Bump RC, Zuspan FP, Bueschling WJ 3rd, Ayers LW, Stephans TJ: The prevalence, six-month persistence, and predictive values of laboratory indicators of bacterial vaginosis (nonspecific vaginitis) in asymptomatic women. Am J Obstet Gynecol 1985;150:917-924.
41. Redondo-Lopez V, Meriwether C, Schmitt C, Opitz M, Cook R, Sobel JD: Vulvovaginal candidiasis complication bacterial vaginosis. Sex Transm Dis 1990;17:51-53.
42. Durfee MA, Forsyth PS, Hale JA, Holmes KK: Ineffectiveness of erythromycin for treatment of Haemophilia vaginalis-associated vaginitis: Possible relationship to acidity of vaginal secretions. Antimicrob Agents Chemother 1979;16:635-637.
43. Symonds J, Biswas AK: Amoxicillin, Augmentin, and metronidazole in bacterial vaginosis associated with Gardnerella vaginalis (letter). Genitourin Med 1986;62:136.
44. Carmona O, Hernandez-Gonzale S, Kobelt R: Ciprofloxacin in the treatment of nonspecific vaginitis. Am J Med 1987;82(suppl 4A):321-323.
45. Vander Meijden WI, Piot P, Loriax SM, Stolz E: Amoxycillin, amoxycillin-clavulanic acid, and metronidazole in the treatment of clue cell-positive discharge: A comparative clinical and laboratory study. J Antimicrob Chemother 1987;20:735-742.
46. Ferris DG, Litaker MS, Woodward L, Mathis D, Hendrich J: Treatment of bacterial vaginosis: A comparison of oral metronidazole, metronidazole vaginal gel and clindamycin vaginal cream. J Fam Pract 1995;41:443-449.
47. Ahmed-Jushuf IH, Shahmanesh M, Arya OP: The treatment of bacterial vaginosis with a 3-day course of 2% clindamycin cream: Results of a multicenter, double-blind, placebo-controlled trial. Genitourin Med 1995;71:254-266.
48. Neri A, Rabinerson D, Kaplan B: Bacterial vaginosis: Drugs versus alternative treatment. Obstet Gynecol Surv 1994;49:809-813.
49. Reid G, Bocking A: The potential for probiotics to prevent bacterial vaginosis and preterm labor. Am J Obstet Gynecol 2003;189:1202-1208.
50. Blaszcak DL: Five day vaginal irritation pilot study in rabbits with rifaximin. East Milstone, Bio-Dynamics, 1991.
51. Blaszcak DL: A 28 day vaginal toxicity study of rifaximin in the rabbit. East Milstone, Bio-Dynamics, 1992.
52. Palazzini E, Desai S: Pilot study on the in vivo efficacy of two formulations of rifaximin for the treatment of bacterial vaginosis. Bologna, Alfa Wassermann/Schiapparelli Searle, 1992.
53. Brown LJ, Oliver RD, Loe H: Evaluating periodontal status of US employed adults. J Am Dent Assoc 1990;121:226-232.
54. Armitage GC: Development of a classification system for periodontal diseases and conditions. Ann Periodontol 1999;4:1-6.
55. Mailhot JM, Fried SL: Oral health and wellness: Understanding periodontal health, recognizing disease states and choices in treatment strategies. J Contemp Dent Pract 2003;4:110-121.
56. Lovegrove JM: Dental plaque revisited: Bacteria associated with periodontal disease. J NZ Soc Periodontol 2004;87:7-21.
57. Jeffcoat MK, Reddy MS: Progression of probing attachment loss in adult periodontitis. J Periodontol 1991;62:185-189.
58. Cobb CM: Non-surgical pocket therapy: Mechanical. Ann Periodontol 1996;1:443-490.
59. Wilson TG: Can surgery be justified for patients with periodontitis? Curr Opin Periodontol 1997;4:64-68.
60. Herrera D, Sanz M, Jepsen S, Needleman I, Roldan S: A systematic review on the effect of systemic antimicrobials as an adjunct to scaling and root planing in periodontitis patients. J Clin Periodontol 2002;29(suppl 3):136-159.
61. Haffajee AD, Socransky SS, Gunsolley JC: Systemic anti-infective periodontal therapy. A systematic review. Ann Periodontol 2003;8:115-181.
62. Haffajee AD, Uzel NG, Arguello EI, Torresyap G, Guerrero DM, Socransky SS: Clinical and microbiological changes associated with the use of combined antimicrobial therapies to treat 'refractory' periodontitis. J Clin Periodontol 2004;31:869-877.
63. Hanes PJ, Purvis JP: Local anti-infective therapy: Pharmacological agents. A systematic review. Ann Periodontol 2003;8:79-98.
64. Pavia M, Nobile CG, Bianco A, Angelillo IF: Meta-analysis of local metronidazole in the treatment of chronic periodontitis. J Periodontol 2004;75:830-838.
65. Knoll-Kohler E: Metronidazole dental gel as an alternative to scaling and root planing in the treatment of localized adult periodontitis. Is its efficacy proved? Eur J Oral Sci 1999;107:415-421.
66. Chanchus PA: The rifomycin. Its use in endodontics - Clinical results (in French). Chir Dent Fr 1965;25:69-74.
67. Picchi N, Pizzoni D: Clinical and pharmacological study of rifampicin in dentistry (in Italian). Rass Int Stomatol Prat 1970;21:265-272.
68. Fabris U: First therapeutic results obtained with the use of rifampicin in apical parodontosis (in Italian). Arcisp S Anna Ferrara 1970;23:505-510.
69. Montana Ramonet JM: Rifomycin in dentistry (in Spanish). Rev Esp Estomatol 1970;18:25-34.
70. Mangiante PE, Eftimiadi C, Balbi G, Cortella P, Della Casa P: Rifaximin: A new antibiotic for the topical treatment of periodontal disease (in Italian); in Pierleoni P (ed): Proceedings of the 21st National Congress of the Italian Society of Dentistry and Maxillo-Facial Surgery. Bologna, Monduzzi Editore, 1987, pp 643-646.
71. Dalseno R, Chiarelli P: Controlled and continued delivery of rifaximin and/or other substances. Patent No. WO200441240, 2003.